Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Therapixel is a French MedTech company specializing in the design and commercialization of AI-powered medical imaging software. Their flagship product, MammoScreen®, is an FDA-cleared and CE-marked solution that assists radiologists in breast cancer screening by automatically detecting and characterizing suspicious lesions in mammograms and tomosynthesis. Therapixel aims to improve diagnostic accuracy, streamline workflows, and ultimately enhance patient outcomes in the fight against breast cancer. They leverage cutting-edge deep learning technologies to provide radiologists with a reliable 'AI second opinion'.
Serves as the central hub for research and development, strategic decision-making, product management, and administrative operations for Therapixel's AI solutions in medical imaging.
Modern office facilities situated in a dynamic area of Paris, designed to foster collaboration and innovation among its dedicated team.
A dynamic, innovative, and mission-driven environment focused on leveraging artificial intelligence to improve healthcare outcomes. Therapixel emphasizes collaboration, cutting-edge research, scientific rigor, and a commitment to quality and patient safety.
The Paris headquarters is pivotal for Therapixel's core innovation in AI for radiology, global strategy formulation, regulatory affairs, and coordination of its international commercialization efforts.
Therapixel's AI solutions, particularly MammoScreen®, are utilized by healthcare institutions, hospitals, and radiology practices across multiple regions, primarily in Europe (with CE mark) and North America (with FDA clearance). The company supports its global customer base through direct sales channels, strategic partnerships with imaging equipment manufacturers and distributors, and participation in major radiology conferences worldwide. Their aim is to make advanced AI tools accessible globally to enhance breast cancer screening efficacy and support radiologists.
50 avenue Daumesnil
Paris
ĂŽle-de-France
France
Address: Nice Méridia - REGUS, Immeuble Premium - CS80021, 27 Boulevard de la Digue des Français, 06200 NICE, France
To leverage the technological talent and innovation ecosystem in the Sophia Antipolis area and the South of France, contributing significantly to Therapixel's core technological advancements and product development pipeline.
Address: [Specific street address not publicly detailed, likely a commercial/sales office]
To drive adoption and provide localized support for MammoScreen® and other Therapixel products in the United States, a key market for medical AI technologies.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Therapixel' leadership includes:
Therapixel has been backed by several prominent investors over the years, including:
Over the past year, Therapixel has significantly strengthened its leadership, notably appointing a new Chairman of the Board and a new Chief Commercial Officer to spearhead its global expansion and commercial strategies.
Discover the tools Therapixel uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Therapixel commonly uses the [first_initial][last]@therapixel.com email format. This pattern is prevalent for professional communication within the company.
[first_initial][last]@therapixel.com
Format
jdoe@therapixel.com
Example
90%
Success rate
Business Wire • April 16, 2024
Therapixel announced the appointment of Peter F. Kappel as its new Chairman of the Board of Directors. This strategic move aims to leverage Mr. Kappel's extensive experience in the healthcare and technology sectors to guide Therapixel through its next phase of growth and international expansion....more
PR Newswire • December 12, 2023
Therapixel announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MammoScreen® for use with Digital Breast Tomosynthesis (DBT), also known as 3D mammography. This clearance allows concurrent reading, where AI insights are presented to radiologists as they interpret DBT images....more
Therapixel News • May 23, 2023
Therapixel announced the appointment of Matthieu Leclerc-Chalvet as its new Chief Commercial Officer (CCO). With over 20 years of experience in the medical imaging and AI healthcare industry, Matthieu will lead Therapixel’s global commercial strategy and drive its expansion into new markets....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Therapixel, are just a search away.